Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) major shareholder Marcin Czernik unloaded 4,389 shares of the stock on the open market in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $38.08, for a total transaction of $167,133.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Karyopharm Therapeutics (NASDAQ:KPTI) traded down 2.47% during mid-day trading on Wednesday, hitting $37.85. 169,234 shares of the company’s stock traded hands. Karyopharm Therapeutics has a 1-year low of $15.50 and a 1-year high of $47.98. The stock’s 50-day moving average is $36.34 and its 200-day moving average is $34.61. The company’s market cap is $1.237 billion.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.02) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.50) by $0.52. On average, analysts predict that Karyopharm Therapeutics will post $-2.19 earnings per share for the current fiscal year.

A number of research firms have recently commented on KPTI. Analysts at Leerink Swann cut their price target on shares of Karyopharm Therapeutics from $63.00 to $60.00 in a research note on Friday, August 8th. Analysts at Oppenheimer downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. One investment analyst has rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $52.67.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.